Core Viewpoint - A class action securities fraud lawsuit has been filed against Fluor Corporation, alleging that the company made false statements regarding its financial health and project costs, which negatively impacted shareholders [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for shareholders affected by alleged securities fraud occurring between February 18, 2025, and July 31, 2025 [2]. - The complaint claims that Fluor Corporation concealed rising costs associated with infrastructure projects due to subcontractor errors, price increases, and scheduling delays [3]. - It is alleged that the company's financial guidance for FY 2025 was unreliable, overstating the effectiveness of its risk mitigation strategies and understating the impact of economic uncertainty [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the plaintiffs and has a strong track record in securing recoveries for shareholders [5].

Core Viewpoint - A class action securities fraud lawsuit has been filed against RCI Hospitality Holdings, Inc. to recover losses incurred by shareholders due to alleged fraudulent activities between December 15, 2021, and September 16, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit alleges that RCI Hospitality Holdings, Inc. engaged in tax fraud and bribery to conceal this fraud, leading to an understatement of legal risks and materially false statements regarding the company's business and operations [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the case and has a strong track record of securing significant recoveries for shareholders [5].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for allegedly misleading investors regarding the performance of its North America Fiber Cement segment during the specified class period from May 20, 2025, to August 18, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that James Hardie Industries misrepresented the strength of its North America Fiber Cement segment, stating that demand was strong and inventory levels were normal, despite knowing that distributors were destocking inventory [5]. - Investors who purchased James Hardie common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file a motion with the court by December 23, 2025 [1][3]. - A class has not yet been certified, meaning investors are not represented by counsel unless they retain one [7]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action securities fraud lawsuit has been filed against Dow Inc. by Pomerantz LLP, correcting a previous misstatement regarding the filing firm [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for shareholders affected by alleged securities fraud occurring between January 30, 2025, and July 23, 2025 [2]. - The complaint alleges that Dow Inc. overstated its ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - It is claimed that the true impact of competitive pressures, declining global sales, and product oversupply on Dow's business was significantly understated [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who experienced losses during the specified timeframe are encouraged to visit a provided link to learn about their rights to seek recovery [4]. - Participation in the recovery process is stated to be at no cost or obligation to the shareholders [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a reputable securities litigation firm with a strong track record in securing significant recoveries for shareholders [5]. - The firm has been recognized in the ISS Securities Class Action Services' Top 50 Report for seven consecutive years, indicating its prominence in the field [5].

Core Points - A class action lawsuit has been filed against Cepton, Inc. by Berger Montague on behalf of investors who traded Cepton shares between July 29, 2024, and January 6, 2025 [1][2] - Cepton, a technology company specializing in lidar solutions, was acquired by Koito Manufacturing Co., Ltd. in January 2025, and its stock is no longer publicly traded [2] - The lawsuit alleges that Cepton misrepresented and omitted critical information regarding a competing merger proposal that valued the company at more than double the price offered by Koito [3] - It is claimed that Cepton's CEO had personal financial conflicts that improperly influenced the Board's decision to accept the Koito deal [4] Company Information - Cepton, Inc. is based in San Jose, California, and focuses on developing lidar solutions for automotive and smart infrastructure applications [2] - The company is no longer publicly traded following its acquisition by Koito Manufacturing Co., Ltd. [2] Legal Context - Investors who traded Cepton securities during the specified class period have until December 8, 2025, to seek appointment as lead plaintiff [2] - The lawsuit references documents from a pending case in Delaware that highlight the alleged failure of Cepton's Board to evaluate a competing offer [3]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud affecting investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - Zions Bancorporation is under investigation for possible securities fraud following the disclosure of misrepresentations and defaults related to loans, which has led to a significant drop in its stock price [1][3]. Summary by Sections Investigation and Legal Actions - The Portnoy Law Firm has initiated an investigation into Zions Bancorporation and may file a class action on behalf of investors [1]. - Investors are encouraged to contact the law firm to discuss their legal rights and options for pursuing claims [2]. Financial Disclosure and Impact - On October 15, 2025, Zions Bancorporation revealed it had identified misrepresentations and defaults by borrowers under two commercial loans, leading to a provision for approximately $60 million and a charge-off of $50 million [3]. - Following this announcement, Zions' stock price fell by $7.10, or 13.14%, closing at $46.93 on October 16, 2025, resulting in losses for investors [3].

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Lantheus made false statements and concealed information regarding its revenue outlook and growth potential, particularly related to the product Pylarify [2] - Allegations include that Lantheus misrepresented its understanding of market pricing and competitive dynamics, leading to an overly optimistic sales growth projection for Pylarify [2] Group 2: Investor Information - Investors who suffered losses during the specified period have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Points - A class action securities lawsuit has been filed against Dow Inc. for alleged securities fraud affecting investors between January 30, 2025, and July 23, 2025 [1][2] - The lawsuit claims that Dow Inc. overstated its ability to handle macroeconomic challenges and maintain financial flexibility for dividends, while downplaying the negative impacts of competitive pressures and declining global demand [2] Case Details - The complaint alleges that Dow's public statements were materially false and misleading regarding its financial condition and the severity of market challenges [2] - Specific issues cited include overstated mitigation of macroeconomic and tariff-related headwinds, understated impacts of competitive and pricing pressures, and an oversupply of products in global markets [2] Next Steps - Investors who suffered losses during the specified timeframe have until October 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] - The public statements made by the defendants were materially false and misleading throughout the relevant period [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]